Do analysts recommend RGC or SGP?

Spyglass Pharma has a consensus price target of $45.00, indicating a potential upside of 77.80%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Spyglass Pharma is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Spyglass Pharma 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Which has stronger valuation and earnings, RGC or SGP?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Spyglass Pharma N/A N/A -$39.87M -$6.41 N/A

Is RGC or SGP more profitable?

Regencell Bioscience's return on equity of 0.00% beat Spyglass Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A Spyglass Pharma N/A -216.57% -27.67%

Do analysts recommend MOR or SGP?

Spyglass Pharma has a consensus price target of $45.00, indicating a potential upside of 77.80%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Spyglass Pharma is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Spyglass Pharma 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Is MOR or SGP more profitable?

Spyglass Pharma has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Spyglass Pharma's return on equity of -216.57% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Spyglass Pharma N/A -216.57% -27.67%

Which has higher earnings and valuation, SGP or TRVI?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyglass Pharma N/A N/A -$39.87M -$6.41 N/A Trevi Therapeutics N/A N/A -$42.76M -$0.34 N/A

Is SGP or TRVI more profitable?

Trevi Therapeutics' return on equity of -28.12% beat Spyglass Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Spyglass Pharma N/A -216.57% -27.67% Trevi Therapeutics N/A -28.12% -26.79%

Does the media favor SGP or TRVI?

In the previous week, Trevi Therapeutics had 5 more articles in the media than Spyglass Pharma. MarketBeat recorded 8 mentions for Trevi Therapeutics and 3 mentions for Spyglass Pharma. Trevi Therapeutics' average media sentiment score of 0.18 beat Spyglass Pharma's score of -0.66 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyglass Pharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Trevi Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SGP or ATAI?

In the previous week, Spyglass Pharma had 2 more articles in the media than Atai Beckley. MarketBeat recorded 3 mentions for Spyglass Pharma and 1 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.50 beat Spyglass Pharma's score of -0.66 indicating that Atai Beckley is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyglass Pharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TARS or SGP?

In the previous week, Tarsus Pharmaceuticals had 15 more articles in the media than Spyglass Pharma. MarketBeat recorded 18 mentions for Tarsus Pharmaceuticals and 3 mentions for Spyglass Pharma. Tarsus Pharmaceuticals' average media sentiment score of -0.01 beat Spyglass Pharma's score of -0.66 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Spyglass Pharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Spyglass Pharma (SGP) Competitors

$25.31 +0.56 (+2.26%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$25.50 +0.19 (+0.75%)

As of 08/7/2026 07:34 PM Eastern

Compare

SGP vs. RGC, MOR, TRVI, ATAI, and TARS

Should you buy Spyglass Pharma stock or one of its competitors? MarketBeat compares Spyglass Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spyglass Pharma include Regencell Bioscience (RGC), MorphoSys (MOR), Trevi Therapeutics (TRVI), Atai Beckley (ATAI), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceuticals" industry.

How does Spyglass Pharma compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Spyglass Pharma (NASDAQ:SGP) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

0.1% of Regencell Bioscience shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Spyglass Pharma has a consensus price target of $45.00, indicating a potential upside of 77.80%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Spyglass Pharma is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Spyglass Pharma	N/A	N/A	-$39.87M	-$6.41	N/A

In the previous week, Spyglass Pharma had 3 more articles in the media than Regencell Bioscience. MarketBeat recorded 3 mentions for Spyglass Pharma and 0 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 0.00 beat Spyglass Pharma's score of -0.66 indicating that Regencell Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Regencell Bioscience	Neutral
Spyglass Pharma	Negative

Regencell Bioscience's return on equity of 0.00% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Spyglass Pharma	N/A	-216.57%	-27.67%

Summary

Regencell Bioscience beats Spyglass Pharma on 6 of the 10 factors compared between the two stocks.

How does Spyglass Pharma compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Spyglass Pharma (NASDAQ:SGP) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

18.4% of MorphoSys shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Spyglass Pharma had 3 more articles in the media than MorphoSys. MarketBeat recorded 3 mentions for Spyglass Pharma and 0 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.00 beat Spyglass Pharma's score of -0.66 indicating that MorphoSys is being referred to more favorably in the media.

Company	Overall Sentiment
MorphoSys	Neutral
Spyglass Pharma	Negative

Spyglass Pharma has a consensus price target of $45.00, indicating a potential upside of 77.80%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Spyglass Pharma is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Spyglass Pharma has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Spyglass Pharma's return on equity of -216.57% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Spyglass Pharma	N/A	-216.57%	-27.67%

Spyglass Pharma has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Spyglass Pharma	N/A	N/A	-$39.87M	-$6.41	N/A

Summary

Spyglass Pharma beats MorphoSys on 8 of the 14 factors compared between the two stocks.

How does Spyglass Pharma compare to Trevi Therapeutics?

Spyglass Pharma (NASDAQ:SGP) and Trevi Therapeutics (NASDAQ:TRVI) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	-$39.87M	-$6.41	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A

Spyglass Pharma currently has a consensus target price of $45.00, indicating a potential upside of 77.80%. Trevi Therapeutics has a consensus target price of $26.75, indicating a potential upside of 44.52%. Given Spyglass Pharma's higher probable upside, research analysts clearly believe Spyglass Pharma is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Trevi Therapeutics had 5 more articles in the media than Spyglass Pharma. MarketBeat recorded 8 mentions for Trevi Therapeutics and 3 mentions for Spyglass Pharma. Trevi Therapeutics' average media sentiment score of 0.18 beat Spyglass Pharma's score of -0.66 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Trevi Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.8% of Trevi Therapeutics shares are owned by institutional investors. 15.4% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Trevi Therapeutics' return on equity of -28.12% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	-216.57%	-27.67%
Trevi Therapeutics	N/A	-28.12%	-26.79%

Summary

Trevi Therapeutics beats Spyglass Pharma on 10 of the 13 factors compared between the two stocks.

How does Spyglass Pharma compare to Atai Beckley?

Spyglass Pharma (NASDAQ:SGP) and Atai Beckley (NASDAQ:ATAI) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Spyglass Pharma has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Atai Beckley's return on equity of -89.79% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	-216.57%	-27.67%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

28.4% of Atai Beckley shares are held by institutional investors. 19.8% of Atai Beckley shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Spyglass Pharma currently has a consensus target price of $45.00, suggesting a potential upside of 77.80%. Atai Beckley has a consensus target price of $11.06, suggesting a potential upside of 52.50%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Spyglass Pharma is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Atai Beckley	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.27

Spyglass Pharma has higher earnings, but lower revenue than Atai Beckley. Spyglass Pharma is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	-$39.87M	-$6.41	N/A
Atai Beckley	$4.09M	652.62	-$660.05M	-$2.23	N/A

In the previous week, Spyglass Pharma had 2 more articles in the media than Atai Beckley. MarketBeat recorded 3 mentions for Spyglass Pharma and 1 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.50 beat Spyglass Pharma's score of -0.66 indicating that Atai Beckley is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Atai Beckley beats Spyglass Pharma on 8 of the 15 factors compared between the two stocks.

How does Spyglass Pharma compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Spyglass Pharma (NASDAQ:SGP) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Tarsus Pharmaceuticals currently has a consensus target price of $90.17, indicating a potential upside of 39.17%. Spyglass Pharma has a consensus target price of $45.00, indicating a potential upside of 77.80%. Given Spyglass Pharma's higher probable upside, analysts plainly believe Spyglass Pharma is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Spyglass Pharma has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$606.33M	4.60	-$66.42M	-$1.09	N/A
Spyglass Pharma	N/A	N/A	-$39.87M	-$6.41	N/A

In the previous week, Tarsus Pharmaceuticals had 15 more articles in the media than Spyglass Pharma. MarketBeat recorded 18 mentions for Tarsus Pharmaceuticals and 3 mentions for Spyglass Pharma. Tarsus Pharmaceuticals' average media sentiment score of -0.01 beat Spyglass Pharma's score of -0.66 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Spyglass Pharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Spyglass Pharma has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Tarsus Pharmaceuticals' return on equity of -13.57% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.57%	-8.31%
Spyglass Pharma	N/A	-216.57%	-27.67%

Summary

Tarsus Pharmaceuticals beats Spyglass Pharma on 10 of the 15 factors compared between the two stocks.

Get Spyglass Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGP vs. The Competition

Export

Metric	Spyglass Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$846.19M	$11.85B	$7.01B	$13.00B
Dividend Yield	N/A	2.70%	2.58%	10.20%
P/E Ratio	-3.95	790.97	271.11	25.19
Price / Sales	N/A	743.77	590.29	78.38
Price / Cash	N/A	71.16	71.81	50.72
Price / Book	N/A	10.75	13.25	6.22
Net Income	-$39.87M	$2.78B	$3.45B	$342.66M
7 Day Performance	12.34%	3.36%	4.67%	4.41%
1 Month Performance	26.11%	-0.81%	-1.28%	-1.10%
1 Year Performance	N/A	192.86%	77.33%	23.99%

Spyglass Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGP Spyglass Pharma	2.4781 of 5 stars	$25.31 +2.3%	$45.00 +77.8%	N/A	$846.19M	N/A	N/A	65	Earnings Report Analyst Forecast Lockup Expiration
RGC Regencell Bioscience	0.156 of 5 stars	$6.08 -0.8%	N/A	-61.3%	$3.01B	N/A	N/A	10
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
TRVI Trevi Therapeutics	3.3096 of 5 stars	$18.69 +4.4%	$24.91 +33.3%	+149.5%	$2.66B	N/A	N/A	20	News Coverage Earnings Report Analyst Forecast Gap Up
ATAI Atai Beckley	2.7611 of 5 stars	$7.17 -0.2%	$11.06 +54.3%	+75.5%	$2.64B	$4.09M	N/A	80	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGP) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spyglass Pharma (SGP) Competitors

SGP vs. RGC, MOR, TRVI, ATAI, and TARS

How does Spyglass Pharma compare to Regencell Bioscience?

Summary

How does Spyglass Pharma compare to MorphoSys?

Summary

How does Spyglass Pharma compare to Trevi Therapeutics?

Summary

How does Spyglass Pharma compare to Atai Beckley?

Summary

How does Spyglass Pharma compare to Tarsus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGP vs. The Competition

Spyglass Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spyglass Pharma (SGP) Competitors

SGP vs. RGC, MOR, TRVI, ATAI, and TARS

How does Spyglass Pharma compare to Regencell Bioscience?

Do institutionals and insiders believe in RGC or SGP?

Do analysts recommend RGC or SGP?

Which has stronger valuation and earnings, RGC or SGP?

Does the media prefer RGC or SGP?

Is RGC or SGP more profitable?

Summary

How does Spyglass Pharma compare to MorphoSys?

Do insiders & institutionals believe in MOR or SGP?

Does the media refer more to MOR or SGP?

Do analysts recommend MOR or SGP?

Is MOR or SGP more profitable?

Which has higher valuation & earnings, MOR or SGP?

Summary

How does Spyglass Pharma compare to Trevi Therapeutics?

Which has higher earnings and valuation, SGP or TRVI?

Do analysts recommend SGP or TRVI?

Does the media favor SGP or TRVI?

Do insiders and institutionals believe in SGP or TRVI?

Is SGP or TRVI more profitable?

Summary

How does Spyglass Pharma compare to Atai Beckley?

Is SGP or ATAI more profitable?

Do insiders & institutionals have more ownership in SGP or ATAI?

Do analysts rate SGP or ATAI?

Which has preferable valuation and earnings, SGP or ATAI?

Does the media favor SGP or ATAI?

Summary

How does Spyglass Pharma compare to Tarsus Pharmaceuticals?

Do insiders and institutionals believe in TARS or SGP?

Do analysts rate TARS or SGP?

Which has higher valuation and earnings, TARS or SGP?

Does the media prefer TARS or SGP?

Is TARS or SGP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGP vs. The Competition

Spyglass Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools